Mereo BioPharma (MREO) Non-Current Assets (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Non-Current Assets of $580000.0 for Q1 2026, down 59.24% year-over-year from $1.4 million in Q1 2025, and down 35.34% quarter-over-quarter from $897000.0 in Q4 2025.
Mereo BioPharma (MREO) Non-Current Assets (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Non-Current Assets for 10 consecutive years, with $580000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 59.24% year-over-year to $580000.0; the TTM figure through Mar 2026 stood at $3.9 million (down 46.54% YoY), while the FY2025 annual figure was $897000.0, down 44.87% from the prior year.
- Non-Current Assets eased to $580000.0 in Q1 2026 per MREO's latest filing, from $897000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.7 million in Q4 2023 and bottomed at -$103.0 million in Q2 2022.
- Historically, Non-Current Assets has averaged -$17.5 million across 5 years, with a median of $1.2 million in 2025.
- Annual changes were most pronounced in 2023 — Non-Current Assets surged 103.76% — and 2026, when it plunged 59.24%.
- Mereo BioPharma's Non-Current Assets stood at -$72.9 million in 2022, then soared by 103.76% to $2.7 million in 2023, then sank by 40.6% to $1.6 million in 2024, then slumped by 44.87% to $897000.0 in 2025, then sank by 35.34% to $580000.0 in 2026.
- Business Quant data shows MREO's Non-Current Assets at $580000.0 in Q1 2026, $897000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Mn |
| Mar 31, 2026 | 580,000.00 |
| Dec 31, 2025 | 897,000.00 |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.21 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | 2.02 Mn |
| Jun 30, 2024 | 2.19 Mn |
| Mar 31, 2024 | 2.44 Mn |
| Dec 31, 2023 | 2.74 Mn |
| Jun 30, 2023 | -67.86 Mn |
| Dec 31, 2022 | -72.88 Mn |
| Jun 30, 2022 | -103.02 Mn |
| Dec 31, 2021 | -133.89 Mn |
| Jun 30, 2021 | -168.20 Mn |
| Dec 31, 2020 | -39.25 Mn |
| Jun 30, 2020 | 53.52 Mn |
| Dec 31, 2019 | 72.02 Mn |
| Jun 30, 2019 | 74.94 Mn |